Cargando…

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade

Immune checkpoint inhibitors (ICI) are used in the treatment of urothelial and renal cell cancers. While some patients may have exceptional responses, better predictive biomarkers are needed. We profiled the circulating immune compartment of patients receiving ICI to identify possible immune markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavoie, Jean-Michel, Baichoo, Priya, Chavez, Elizabeth, Nappi, Lucia, Khalaf, Daniel, Kollmannsberger, Christian K., Chi, Kim N., Weng, Andrew, Steidl, Christian, Eigl, Bernhard J., Nissen, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513023/
https://www.ncbi.nlm.nih.gov/pubmed/36176410
http://dx.doi.org/10.3389/fonc.2022.973402
_version_ 1784797962148249600
author Lavoie, Jean-Michel
Baichoo, Priya
Chavez, Elizabeth
Nappi, Lucia
Khalaf, Daniel
Kollmannsberger, Christian K.
Chi, Kim N.
Weng, Andrew
Steidl, Christian
Eigl, Bernhard J.
Nissen, Michael
author_facet Lavoie, Jean-Michel
Baichoo, Priya
Chavez, Elizabeth
Nappi, Lucia
Khalaf, Daniel
Kollmannsberger, Christian K.
Chi, Kim N.
Weng, Andrew
Steidl, Christian
Eigl, Bernhard J.
Nissen, Michael
author_sort Lavoie, Jean-Michel
collection PubMed
description Immune checkpoint inhibitors (ICI) are used in the treatment of urothelial and renal cell cancers. While some patients may have exceptional responses, better predictive biomarkers are needed. We profiled the circulating immune compartment of patients receiving ICI to identify possible immune markers associated with immunotherapy response or resistance. Peripheral blood samples were collected prior to, and 3 weeks after initiation of ICI. Using mass cytometry, 26 distinct immune populations were identified. Responders to immune checkpoint inhibitors had higher frequencies of naïve CD4+ T-cells, and lower frequencies of CD161+ Th17 cells and CCR4+ Th2 cells. Non-responders had a higher frequency of circulating PD1+ T-cells at baseline; there was a subsequent decrease in frequency with exposure to ICI with a concomitant increase in Ki67 expression. Flow cytometry for cytokines and chemokine receptors showed that CD4+ T cells of non-responder patients expressed less CXCR4 and CCR7. In addition, their PD1- CD4+ T cells had higher TNFα and higher CCR4 expression, while their PD1+ CD4+ T cells had higher interferon γ and lower CCR4 expression. The role of γ/δ T-cells was also explored. In responders, these cells had higher levels of interferon γ, TNFα and CCR5. One patient with a complete response had markedly higher frequency of γ/δ T-cells at baseline, and an expansion of these cells after treatment. This case was analyzed using single-cell gene expression profiling. The bulk of the γ/δ T cells consisted of a single clone of Vγ9/Vδ2 cells both before and after expansion, although the expansion was polyclonal. Gene expression analysis showed that exposure to an ICI led to a more activated phenotype of the γ/δ T cells. In this study, the circulating immune compartment was shown to have potential for biomarker discovery. Its dynamic changes during treatment may be used to assess response before radiographic changes are apparent, and these changes may help us delineate mechanisms that underpin both response and resistance to ICI. It also hypothesizes a potential role for γ/δ T cells as effector cells in some cases.
format Online
Article
Text
id pubmed-9513023
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95130232022-09-28 Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade Lavoie, Jean-Michel Baichoo, Priya Chavez, Elizabeth Nappi, Lucia Khalaf, Daniel Kollmannsberger, Christian K. Chi, Kim N. Weng, Andrew Steidl, Christian Eigl, Bernhard J. Nissen, Michael Front Oncol Oncology Immune checkpoint inhibitors (ICI) are used in the treatment of urothelial and renal cell cancers. While some patients may have exceptional responses, better predictive biomarkers are needed. We profiled the circulating immune compartment of patients receiving ICI to identify possible immune markers associated with immunotherapy response or resistance. Peripheral blood samples were collected prior to, and 3 weeks after initiation of ICI. Using mass cytometry, 26 distinct immune populations were identified. Responders to immune checkpoint inhibitors had higher frequencies of naïve CD4+ T-cells, and lower frequencies of CD161+ Th17 cells and CCR4+ Th2 cells. Non-responders had a higher frequency of circulating PD1+ T-cells at baseline; there was a subsequent decrease in frequency with exposure to ICI with a concomitant increase in Ki67 expression. Flow cytometry for cytokines and chemokine receptors showed that CD4+ T cells of non-responder patients expressed less CXCR4 and CCR7. In addition, their PD1- CD4+ T cells had higher TNFα and higher CCR4 expression, while their PD1+ CD4+ T cells had higher interferon γ and lower CCR4 expression. The role of γ/δ T-cells was also explored. In responders, these cells had higher levels of interferon γ, TNFα and CCR5. One patient with a complete response had markedly higher frequency of γ/δ T-cells at baseline, and an expansion of these cells after treatment. This case was analyzed using single-cell gene expression profiling. The bulk of the γ/δ T cells consisted of a single clone of Vγ9/Vδ2 cells both before and after expansion, although the expansion was polyclonal. Gene expression analysis showed that exposure to an ICI led to a more activated phenotype of the γ/δ T cells. In this study, the circulating immune compartment was shown to have potential for biomarker discovery. Its dynamic changes during treatment may be used to assess response before radiographic changes are apparent, and these changes may help us delineate mechanisms that underpin both response and resistance to ICI. It also hypothesizes a potential role for γ/δ T cells as effector cells in some cases. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513023/ /pubmed/36176410 http://dx.doi.org/10.3389/fonc.2022.973402 Text en Copyright © 2022 Lavoie, Baichoo, Chavez, Nappi, Khalaf, Kollmannsberger, Chi, Weng, Steidl, Eigl and Nissen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lavoie, Jean-Michel
Baichoo, Priya
Chavez, Elizabeth
Nappi, Lucia
Khalaf, Daniel
Kollmannsberger, Christian K.
Chi, Kim N.
Weng, Andrew
Steidl, Christian
Eigl, Bernhard J.
Nissen, Michael
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title_full Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title_fullStr Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title_full_unstemmed Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title_short Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
title_sort comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513023/
https://www.ncbi.nlm.nih.gov/pubmed/36176410
http://dx.doi.org/10.3389/fonc.2022.973402
work_keys_str_mv AT lavoiejeanmichel comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT baichoopriya comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT chavezelizabeth comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT nappilucia comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT khalafdaniel comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT kollmannsbergerchristiank comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT chikimn comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT wengandrew comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT steidlchristian comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT eiglbernhardj comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade
AT nissenmichael comprehensiveimmuneprofilingofpatientswithadvancedurothelialorrenalcellcarcinomareceivingimmunecheckpointblockade